New drug cocktails aim to tackle tough myeloma

NCT ID NCT02343042

Recruiting now Disease control Sponsor: Karyopharm Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests the drug selinexor in combination with various standard treatments for multiple myeloma, a type of blood cancer. It involves 300 participants with either relapsed/refractory or newly diagnosed disease. The goal is to find safe and effective doses and to see if these combinations improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selinexor (also known as XPOVIO) combined with various standard myeloma drugs
What this could lead to: If successful, this could provide more effective treatment options for multiple myeloma patients, potentially improving response rates and delaying disease progression.
What could go wrong: This is an early-phase trial (1b/2) with many different drug combinations, so results may vary. Side effects from the combinations could be significant, and not all arms may prove effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING

Gilbert, Arizona, 85234, United States
Cancer Care Manitoba
ACTIVE_NOT_RECRUITING

Winnipeg, Manitoba, R3E 0V9, Canada
Columbia University
COMPLETED

New York, New York, 10032, United States
Cross Cancer Institute / University of Alberta
COMPLETED

Edmonton, Alberta, T6G 1Z2, Canada
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke Institute of Cancer/ Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Fred Hutch Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Hackensack University Medical Center - John Theurer Cancer Center
ACTIVE_NOT_RECRUITING

Hackensack, New Jersey, 07601, United States
Jonnsson Comprehensive Cancer Center / University of Los Angeles
ACTIVE_NOT_RECRUITING

Los Angeles, California, 0095, United States
Maisonneuve-Rosemont Hospital
COMPLETED

Montreal, Quebec, H1T 2M4, Canada
Massachusetts General Hospital
COMPLETED

Boston, Massachusetts, 02114, United States
Memorial Hospital of Newfoundland
COMPLETED

St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Princess Margaret Cancer Centre
ACTIVE_NOT_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth II Health Sciences Center
ACTIVE_NOT_RECRUITING

Halifax, Nova Scotia, B3H 2Y9, Canada
Royal Victoria Hospital / McGill University
COMPLETED

Montreal, Quebec, H3A 1A1, Canada
Sarah Cannon- Tennessee Oncology Nashville
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon-Colorado Blood Cancer Institute
WITHDRAWN

Denver, Colorado, 80218, United States
Swedish Cancer Institute
COMPLETED

Seattle, Washington, 98109, United States
Tom Baker Cancer Center/Alberta Health Services
COMPLETED

Calgary, Alberta, T2N 4Z6, Canada
University of Nebraska Medical Center
COMPLETED

Omaha, Nebraska, 68198, United States
University of North Carolina - Chapel Hill Comprehensive Cancer Center
ACTIVE_NOT_RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Wisconsin School of Medicine and Public Health
ACTIVE_NOT_RECRUITING

Madison, Wisconsin, 53792, United States
Vancouver General Hospital
COMPLETED

Vancouver, British Columbia, V5Z 1M9, Canada
Weill Cornell Medicine
COMPLETED

New York, New York, 10065, United States
Wilmot Cancer Center/ University of Rochester
ACTIVE_NOT_RECRUITING

Rochester, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.